MX2016004944A - Compuesto biciclico que contiene azufre. - Google Patents
Compuesto biciclico que contiene azufre.Info
- Publication number
- MX2016004944A MX2016004944A MX2016004944A MX2016004944A MX2016004944A MX 2016004944 A MX2016004944 A MX 2016004944A MX 2016004944 A MX2016004944 A MX 2016004944A MX 2016004944 A MX2016004944 A MX 2016004944A MX 2016004944 A MX2016004944 A MX 2016004944A
- Authority
- MX
- Mexico
- Prior art keywords
- effects
- sulfur
- containing bicyclic
- pam
- schizophrenia
- Prior art date
Links
- -1 bicyclic compound Chemical class 0.000 title abstract 3
- 229910052717 sulfur Inorganic materials 0.000 title abstract 3
- 239000011593 sulfur Substances 0.000 title abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000694 effects Effects 0.000 abstract 4
- 229940126027 positive allosteric modulator Drugs 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000000980 schizophrenia Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000003463 sulfur Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se provee un compuesto que es útil como una composición farmacéutica para la prevención y/o el tratamiento de esquizofrenia, daño cognitivo asociado con esquizofrenia (CIAS), deterioro cognitivo, síndrome de X frágil, trastorno de espectro autista, espasticidad, trastorno de ansiedad, adicción a sustancias, dolor, fibromialgia, síndrome de Charcot-Marie-Tooth, o similares afecciones. Los presentes inventores han estudiado que una composición farmacéutica para la prevención y/o el tratamiento de esquizofrenia, daño cognitivo asociado con esquizofrenia (CIAS), deterioro cognitivo, síndrome de X frágil, trastorno de espectro autista, espasticidad, trastorno de ansiedad, adicción a sustancias, dolor, fibromialgia, síndrome de Charcot-Marie-Tooth, o similares, que tiene un modulador alostérico positivo (acción PAM) de GABAB, y han hallado que un compuesto bicíclico que contiene azufre es un PAM de un receptor GABAB, de modo de completar así la presente invención. El compuesto bicíclico que contiene azufre de la presente invención tiene una acción PAM de GABAB, y puede usarse como un agente para la prevención y/o el tratamiento de esquizofrenia, CIAS, deterioro cognitivo, síndrome de X frágil, trastorno de espectro autista, espasticidad, trastorno de ansiedad, adicción a sustancias, dolor, fibromialgia, o síndrome de Charcot-Marie-Tooth.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013216332 | 2013-10-17 | ||
| PCT/JP2014/077653 WO2015056771A1 (ja) | 2013-10-17 | 2014-10-17 | 含硫黄二環式化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004944A true MX2016004944A (es) | 2016-07-11 |
| MX367857B MX367857B (es) | 2019-09-09 |
Family
ID=52826697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004944A MX367857B (es) | 2013-10-17 | 2014-10-17 | Compuesto bicíclico que contiene azufre. |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9051339B2 (es) |
| EP (1) | EP3059239B1 (es) |
| JP (1) | JP6477484B2 (es) |
| KR (1) | KR102248450B1 (es) |
| CN (1) | CN105636965B (es) |
| AR (1) | AR098070A1 (es) |
| AU (1) | AU2014335304B2 (es) |
| BR (1) | BR112016008654B8 (es) |
| CA (1) | CA2927518C (es) |
| CY (1) | CY1120880T1 (es) |
| DK (1) | DK3059239T3 (es) |
| EA (1) | EA029075B1 (es) |
| ES (1) | ES2685070T3 (es) |
| HR (1) | HRP20181183T1 (es) |
| HU (1) | HUE040208T2 (es) |
| IL (1) | IL244953B (es) |
| LT (1) | LT3059239T (es) |
| MX (1) | MX367857B (es) |
| MY (1) | MY177271A (es) |
| NZ (1) | NZ719149A (es) |
| PH (1) | PH12016500625A1 (es) |
| PL (1) | PL3059239T3 (es) |
| PT (1) | PT3059239T (es) |
| RS (1) | RS57532B1 (es) |
| SA (1) | SA516370956B1 (es) |
| SG (1) | SG11201602926UA (es) |
| SI (1) | SI3059239T1 (es) |
| SM (1) | SMT201800431T1 (es) |
| TW (1) | TWI648281B (es) |
| UA (1) | UA116042C2 (es) |
| WO (1) | WO2015056771A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| WO2019155765A1 (ja) | 2018-02-06 | 2019-08-15 | 株式会社瑞光 | 伸縮シート及び伸縮シートを用いた使い捨て着用物品、並びにそれらの製造方法 |
| MY199646A (en) * | 2018-08-31 | 2023-11-14 | Astellas Pharma Inc | Pharmaceutical composition for oral administration |
| IL300208A (en) | 2020-08-05 | 2023-03-01 | Richter Gedeon Nyrt | Pharmacologically active heterocyclic substituted pyrazolo[5,1-a]pyrimidine derivatives |
| WO2023028519A2 (en) | 2021-08-27 | 2023-03-02 | Astellas Pharma Global Development, Inc. | Methods of treating substance use disorder |
| JP2025157626A (ja) * | 2022-09-01 | 2025-10-16 | アステラス製薬株式会社 | ６－（４，４－ジメチルシクロヘキシル）－４－［（１，１－ジオキソ－１λ６－チオモルホリン－４－イル）メチル］－２－メチルチエノ［２，３－ｄ］ピリミジンまたはその塩の製造方法 |
| AU2024256911A1 (en) * | 2023-04-21 | 2025-11-20 | Xizang Haisco Pharmaceutical Co., Ltd. | Cyp11a1 inhibitors and use thereof |
| CN117263951A (zh) * | 2023-09-13 | 2023-12-22 | 广东莱佛士制药技术有限公司 | 6-溴-2-甲基噻吩并[2,3-d]嘧啶-4-甲腈的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001097979A (ja) | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
| WO2002062803A1 (en) | 2001-02-08 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Thienopyrimidine derivative |
| JP2002308882A (ja) * | 2001-02-08 | 2002-10-23 | Yamanouchi Pharmaceut Co Ltd | チエノピリミジン誘導体 |
| KR20060013370A (ko) * | 2003-03-31 | 2006-02-09 | 프레딕스 파마슈티컬스 홀딩즈, 인코포레이티드 | 신규한 피페리디닐아미노-티에노[2,3-ｄ]피리미딘 화합물 |
| US7723324B2 (en) * | 2003-10-28 | 2010-05-25 | Sepracor, Inc. | Imidazo[1,2-A]pyridine anxiolytics |
| GB0416168D0 (en) | 2004-07-20 | 2004-08-18 | Vernalis Cambridge Ltd | Pyrmidothiophene compounds |
| GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| BRPI0519521A2 (pt) * | 2004-12-17 | 2009-02-10 | Hoffmann La Roche | derivados de tieno-piridina como aumentadores alostÉricos gaba-b |
| PL2041139T3 (pl) | 2006-04-26 | 2012-05-31 | Hoffmann La Roche | Związki farmaceutyczne |
| JP5647998B2 (ja) | 2009-03-13 | 2015-01-07 | カトリーケ ユニバーシテイト ルーヴェン、ケー．ユー． ルーヴェン アール アンド ディー | 免疫抑制剤としてのチアゾロピリミジン調節因子 |
| EP2473054B1 (en) * | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
| GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
-
2014
- 2014-10-16 TW TW103135823A patent/TWI648281B/zh not_active IP Right Cessation
- 2014-10-17 NZ NZ71914914A patent/NZ719149A/en not_active IP Right Cessation
- 2014-10-17 LT LTEP14853825.9T patent/LT3059239T/lt unknown
- 2014-10-17 AU AU2014335304A patent/AU2014335304B2/en not_active Ceased
- 2014-10-17 US US14/517,229 patent/US9051339B2/en active Active
- 2014-10-17 SI SI201430780T patent/SI3059239T1/en unknown
- 2014-10-17 WO PCT/JP2014/077653 patent/WO2015056771A1/ja not_active Ceased
- 2014-10-17 MY MYPI2016701379A patent/MY177271A/en unknown
- 2014-10-17 EP EP14853825.9A patent/EP3059239B1/en active Active
- 2014-10-17 SM SM20180431T patent/SMT201800431T1/it unknown
- 2014-10-17 CA CA2927518A patent/CA2927518C/en active Active
- 2014-10-17 AR ARP140103875A patent/AR098070A1/es active IP Right Grant
- 2014-10-17 DK DK14853825.9T patent/DK3059239T3/en active
- 2014-10-17 UA UAA201605245A patent/UA116042C2/uk unknown
- 2014-10-17 SG SG11201602926UA patent/SG11201602926UA/en unknown
- 2014-10-17 ES ES14853825.9T patent/ES2685070T3/es active Active
- 2014-10-17 BR BR112016008654A patent/BR112016008654B8/pt not_active IP Right Cessation
- 2014-10-17 HR HRP20181183TT patent/HRP20181183T1/hr unknown
- 2014-10-17 PL PL14853825T patent/PL3059239T3/pl unknown
- 2014-10-17 CN CN201480057239.0A patent/CN105636965B/zh not_active Expired - Fee Related
- 2014-10-17 HU HUE14853825A patent/HUE040208T2/hu unknown
- 2014-10-17 EA EA201690790A patent/EA029075B1/ru not_active IP Right Cessation
- 2014-10-17 MX MX2016004944A patent/MX367857B/es active IP Right Grant
- 2014-10-17 JP JP2015542677A patent/JP6477484B2/ja not_active Expired - Fee Related
- 2014-10-17 RS RS20180865A patent/RS57532B1/sr unknown
- 2014-10-17 KR KR1020167011628A patent/KR102248450B1/ko active Active
- 2014-10-17 PT PT14853825T patent/PT3059239T/pt unknown
-
2015
- 2015-04-17 US US14/689,748 patent/US9642852B2/en not_active Expired - Fee Related
-
2016
- 2016-04-06 IL IL244953A patent/IL244953B/en active IP Right Grant
- 2016-04-06 PH PH12016500625A patent/PH12016500625A1/en unknown
- 2016-04-16 SA SA516370956A patent/SA516370956B1/ar unknown
-
2018
- 2018-08-14 CY CY20181100858T patent/CY1120880T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004944A (es) | Compuesto biciclico que contiene azufre. | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| PH12018500065B1 (en) | Oxysterols and methods of use thereof | |
| MX351581B (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| MX2018005041A (es) | Compuestos para tratar la esclerosis lateral amiotrofica. | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| GEAP202115121A (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| MY170262A (en) | Dicarboxylic acid compound | |
| PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
| MX2016015467A (es) | Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos. | |
| MX362879B (es) | Usos novedosos. | |
| GEP20156315B (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| SA521431279B1 (ar) | D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي | |
| PH12015502032A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX2015011198A (es) | Compuestos antivirales. | |
| MY176727A (en) | Selective androgen receptor modulators | |
| IN2014DN09314A (es) | ||
| PH12018500668A1 (en) | Therapeutic compounds and methods of use thereof | |
| EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| PH12015502341A1 (en) | Heterocyclic acetic acid amide compound | |
| MX2018016339A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| MX2015010790A (es) | Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc. | |
| NZ707773A (en) | Methods of treating liver diseases | |
| MX2019015747A (es) | Compuesto heterociclico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |